Bruker Co. (NASDAQ:BRKR) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 2,550,600 shares, a growth of 14.5% from the April 30th total of 2,228,100 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average daily volume of 809,500 shares, the short-interest ratio is currently 3.2 days.
BRKR stock traded up $0.52 during midday trading on Wednesday, reaching $47.71. 489,468 shares of the company’s stock traded hands, compared to its average volume of 750,746. The firm has a market capitalization of $7.20 billion, a PE ratio of 34.08, a price-to-earnings-growth ratio of 2.32 and a beta of 1.26. The company has a current ratio of 2.12, a quick ratio of 1.27 and a debt-to-equity ratio of 0.42. Bruker has a 52 week low of $26.10 and a 52 week high of $47.78.
Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.04. The business had revenue of $461.40 million during the quarter, compared to analyst estimates of $450.46 million. Bruker had a net margin of 9.53% and a return on equity of 26.28%. Bruker’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.24 EPS. On average, equities analysts predict that Bruker will post 1.62 earnings per share for the current fiscal year.
Several analysts have recently weighed in on the stock. UBS Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $43.00 price objective for the company in a research note on Friday, May 3rd. BidaskClub lowered shares of Bruker from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. Wolfe Research assumed coverage on shares of Bruker in a research note on Thursday, May 30th. They issued a “peer perform” rating for the company. Deutsche Bank upgraded shares of Bruker from a “hold” rating to a “buy” rating and lifted their price objective for the company from $40.00 to $50.00 in a research note on Friday, April 12th. Finally, Zacks Investment Research lowered shares of Bruker from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Bruker currently has a consensus rating of “Buy” and a consensus target price of $43.71.
In other news, CEO Frank H. Laukien sold 400,000 shares of Bruker stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $41.48, for a total value of $16,592,000.00. Following the completion of the sale, the chief executive officer now owns 37,991,030 shares in the company, valued at approximately $1,575,867,924.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Marc A. Kastner sold 1,374 shares of Bruker stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $41.79, for a total transaction of $57,419.46. Following the completion of the sale, the director now owns 10,811 shares of the company’s stock, valued at approximately $451,791.69. The disclosure for this sale can be found here. Insiders sold a total of 801,374 shares of company stock worth $33,241,419 in the last 90 days. Corporate insiders own 26.50% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its stake in shares of Bruker by 33.4% during the third quarter. JPMorgan Chase & Co. now owns 96,033 shares of the medical research company’s stock valued at $3,213,000 after acquiring an additional 24,048 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Bruker by 0.9% during the third quarter. TIAA CREF Investment Management LLC now owns 922,156 shares of the medical research company’s stock worth $30,846,000 after purchasing an additional 8,528 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Bruker by 3.3% during the fourth quarter. Rhumbline Advisers now owns 102,048 shares of the medical research company’s stock worth $3,038,000 after purchasing an additional 3,254 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Bruker during the fourth quarter worth about $176,000. Finally, Chicago Equity Partners LLC lifted its position in shares of Bruker by 4.4% during the fourth quarter. Chicago Equity Partners LLC now owns 9,415 shares of the medical research company’s stock worth $280,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 66.73% of the company’s stock.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: CD Ladder
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.